Cargando…

MLL1 is central to macrophage-mediated inflammation

Detalles Bibliográficos
Autor principal:	Schaller, Matthew A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by The American Society of Hematology 2023
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933578/ https://www.ncbi.nlm.nih.gov/pubmed/36795448 http://dx.doi.org/10.1182/blood.2022019181

Ejemplares similares

The histone methyltransferase MLL1/KMT2A in monocytes drives coronavirus-associated coagulopathy and inflammation
por: Sharma, Sriganesh B., et al.
Publicado: (2023)

Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model
por: Rafiei Hashtchin, Anna, et al.
Publicado: (2021)

GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
por: Wang, Dongyao, et al.
Publicado: (2022)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
por: Shaw, Lauren C., et al.
Publicado: (2022)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

The identification of TCF1(+) progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
por: Tabanelli, Valentina, et al.
Publicado: (2022)

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
por: Lecomte, Sara, et al.
Publicado: (2023)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases
por: Martin Merinero, Héctor, et al.
Publicado: (2021)

4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
por: Swatler, Julian, et al.
Publicado: (2022)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
por: Dean, Erin A., et al.
Publicado: (2023)

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
por: Nicolai, Leo, et al.
Publicado: (2022)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
por: Little, Jessica S., et al.
Publicado: (2023)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma
por: Ferrari, Nicola, et al.
Publicado: (2021)

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
por: Kim, Alexander B., et al.
Publicado: (2023)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

Neutrophil transit time and localization within the megakaryocyte define morphologically distinct forms of emperipolesis
por: Huang, Frank Y., et al.
Publicado: (2022)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Intravital imaging of three different microvascular beds in SARS-CoV-2–infected mice
por: Castanheira, Fernanda V. S., et al.
Publicado: (2023)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination
por: Lee, Hye Kyung, et al.
Publicado: (2023)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
por: Keller, Michael D., et al.
Publicado: (2020)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment
por: Bourne, Christopher M., et al.
Publicado: (2022)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
por: Perez de Acha, Olivia, et al.
Publicado: (2023)

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
por: McNerney, Kevin O., et al.
Publicado: (2023)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_glr4esbjvbkjai899sh6cmfh70